Patient-specific alpha-particle dosimetry.
Alpha-particle therapy has received increased attention during the last few years because of the development of new targeting constructs and new labeling techniques and the availability of suitable α-particle - emitting radionuclides. This work provides an overview of methods that have been used in clinical trials in estimating the absorbed dose to tumors and healthy tissue in patients following such α-particle therapy. Similarities and differences compared to conventional therapies using β¯-particle emitters are presented. The specific challenges of establishing accurate dosimetry for α- particles in the individual patient are also discussed, as is the effect that improved patient-specific dosimetry might have on the overall efficacy of this type of therapy.
Dosimetry and Medical Radiation Physics Section, International Atomic Energy Agency (IAEA), Vienna, Austria.
Stig
S
Palm
Jörgen
J
Elgqvist
Lars
L
Jacobsson
D000512:Alpha Particles / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001932:Brain Neoplasms / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D005260:Female; D005910:Glioma / Q000532:radiotherapy; D006801:Humans; D007951:Leukemia, Myeloid / Q000532:radiotherapy; D009369:Neoplasms / Q000532:radiotherapy*; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D011874:Radiometry